Surface Proteomics Reveals CD72 as a Target for
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
29
02
2020
revised:
09
02
2021
accepted:
12
03
2021
pubmed:
18
3
2021
medline:
26
2
2022
entrez:
17
3
2021
Statut:
ppublish
Résumé
Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis
Identifiants
pubmed: 33727310
pii: 2159-8290.CD-20-0242
doi: 10.1158/2159-8290.CD-20-0242
pmc: PMC8338785
mid: NIHMS1686861
doi:
Substances chimiques
Antigens, CD
0
Antigens, CD19
0
Antigens, Differentiation, B-Lymphocyte
0
CD72 protein, human
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2032-2049Subventions
Organisme : NIGMS NIH HHS
ID : DP2 GM123500
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA184116
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA230188
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA082103
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Leukemia. 2016 Sep;30(9):1920-3
pubmed: 27055873
Blood. 2019 Nov 7;134(19):1585-1597
pubmed: 31558469
Methods Enzymol. 2016;580:21-44
pubmed: 27586327
Cell Rep. 2017 Jan 10;18(2):482-495
pubmed: 28076791
Pediatr Blood Cancer. 2015 Jun;62(6):964-9
pubmed: 25728039
Nat Struct Mol Biol. 2018 Mar;25(3):289-296
pubmed: 29434346
Cell. 2011 Jan 21;144(2):296-309
pubmed: 21241896
Sci Transl Med. 2019 Sep 25;11(511):
pubmed: 31554741
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630
Mol Ther Methods Clin Dev. 2018 Dec 31;12:145-156
pubmed: 30666307
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Elife. 2018 Jan 23;7:
pubmed: 29359686
Leuk Lymphoma. 1995 Jun;18(1-2):119-22
pubmed: 8580813
EMBO Mol Med. 2012 Oct;4(10):1015-28
pubmed: 22837174
Clin Cancer Res. 2019 Sep 1;25(17):5329-5341
pubmed: 31110075
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):6020-6029
pubmed: 30280786
J Immunol. 2008 Jun 1;180(11):7358-67
pubmed: 18490735
Nat Commun. 2019 Jun 26;10(1):2803
pubmed: 31243293
Cell. 2020 Oct 1;183(1):126-142.e17
pubmed: 32961131
Blood. 2016 Jun 30;127(26):3312-20
pubmed: 27207800
Blood. 2017 Mar 2;129(9):1155-1165
pubmed: 28031181
Cancer Discov. 2018 Oct;8(10):1219-1226
pubmed: 30135176
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Cancer Discov. 2012 Nov;2(11):1004-23
pubmed: 23107779
Blood. 2013 Mar 7;121(10):1814-8
pubmed: 23319569
J Mol Biol. 2003 Dec 5;334(4):733-49
pubmed: 14636599
Cancer Cell. 2016 Apr 11;29(4):574-586
pubmed: 27070704
Blood. 2015 Dec 17;126(25):2676-85
pubmed: 26463423
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Nat Biotechnol. 2009 Apr;27(4):378-86
pubmed: 19349973
Am J Hematol. 1992 Nov;41(3):151-8
pubmed: 1384316
Signal Transduct Target Ther. 2016 Mar 11;1:16002
pubmed: 29263894
Cell Adh Migr. 2014;8(6):563-77
pubmed: 25482635
Leukemia. 2019 Dec;33(12):2854-2866
pubmed: 31110217
Nature. 2009 Jun 4;459(7247):717-21
pubmed: 19412164
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Immunol Rev. 2019 Jul;290(1):39-59
pubmed: 31355492
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551
pubmed: 30988175
Nat Rev Cancer. 2018 Feb;18(2):103-116
pubmed: 29302068
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Cell. 2014 Oct 23;159(3):647-61
pubmed: 25307932
Blood Adv. 2019 Apr 23;3(8):1230-1243
pubmed: 30979721
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Blood. 2011 May 5;117(18):4736-45
pubmed: 21406718
Cancer Res. 2009 Mar 15;69(6):2358-64
pubmed: 19258515
J Immunol. 2013 Jun 1;190(11):5436-45
pubmed: 23616572
Leukemia. 2015 Oct;29(10):2039-49
pubmed: 25975191
Clin Cancer Res. 2019 Dec 1;25(23):7046-7057
pubmed: 31439577